Quest Diagnostics Incorporated

NYSE:DGX

Medical - Diagnostics & Research

Healthcare
$259.69 -1.72%

-$3.41 today

Market cap
$28.57B
Beta
0.59
P/E (TTM)
20.9
EPS (TTM)
$9.31
Dividend yield
1.68%
52W Low $164.65High $213.50

Volume 1.30M

Average 0.91M

DGX Other Financing Activities

Financing cash flows not reported separately.

Quest Diagnostics IncorporatedNYSE: DGX

Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026

Other financing activities growth accelerates

Q3 FY2026 other financing activities of $377M (cash outflow) rose 1296.3% year over year, ahead of the +573.2% change in trailing-twelve-month other financing activities. Sequentially, it rose 183.5% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Other financing activities amounted to 0.6% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Other financing activities increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1296.3% holds above the trailing-twelve-month pace of +573.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$377M+183.5% QoQ
Last fiscal yearDec 2025
-$62M-369.6% YoY
LTMSep 2026
-$552M+573.2% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1296.3%——
1 year-369.6%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(62M) USD
Year-over-year change
-369.6%

Other Financing Activities vs competitors

How DGX compares with its peers on the latest reported figures

  • DGX's LTM Sep 2026 other financing activities of $552M is the largest of the 9 companies compared; the peer median is $3.65M.
  • Its year-over-year change of +573.2% is the 3rd highest of 7, against a peer median of +37.5%.
  • Other financing activities amounts to 4.7% of revenue for DGX, versus a peer median of 5.5%.
DGX Competitors Peer median
Other Financing Activities for DGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DGXQuest Diagnostics IncorporatedLTM Sep 2026$552M +573.2%+53.9%4.7%
GRALGRAIL, Inc.LTM Jun 2026$423.32M ——256.1%
ILMNIllumina, Inc.LTM Jun 2026$397M -69.3%-8.8%8.8%
LHLabcorp Holdings Inc.LTM Jun 2026$311.8M -157.1%—2.2%
GHGuardant Health, Inc.LTM Sep 2026$282.06M +866.3%-30.2%22.1%
RDNTRadNet, Inc.LTM Sep 2026$254.24M +144.4%+71.0%10.7%
QGENQiagen N.V.LTM Jun 2026$21.52M -104.5%—1.0%
NTRANatera, Inc.LTM Jun 2026$5.1M ——0.2%
RVTYRevvity, Inc.LTM Jul 2026$2.21M +844.4%+71.0%0.1%
Peer median (excluding DGX) $3.65M+37.5%+31.1%5.5%

Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.08B1.02B908M921M1.05B
Depreciation & Amortization408M437M439M493M570M
Deferred Income Tax(57M)1M(49M)13M105M
Stock-Based Compensation79M77M77M88M88M
Change in Working Capital87M119M(145M)(201M)50M
Accounts Receivables81M246M(15M)(71M)(106M)
Inventory(20M)0000
Accounts Payables35M(149M)(55M)(67M)129M
Other Working Capital(9M)22M(75M)(63M)27M
Other Non-Cash Items(364M)69M42M20M27M
Operating Cash Flow2.23B1.72B1.27B1.33B1.89B
Capital Expenditures(403M)(404M)(408M)(425M)(527M)
Acquisitions (Net)424M(144M)(611M)(2.16B)(101M)
Purchases of Investments(3M)(5M)000
Sales of Investments403M5M000
Other Investing Activities(400M)5M(42M)41M(3M)
Investing Cash Flow21M(543M)(1.06B)(2.55B)(631M)
Debt Repayment(2M)(2M)748M1.54B(602M)
Common Stock Issued000079M
Common Stock Repurchased(2.2B)(1.41B)(275M)(151M)(450M)
Dividends Paid(309M)(305M)(314M)(331M)(353M)
Other Financing Activities(30M)(17M)1M23M(62M)
Financing Cash Flow(2.54B)(1.73B)160M1.08B(1.39B)
Effect of Forex Changes000(7M)4M
Net Change in Cash(286M)(557M)371M(137M)(129M)
Free Cash Flow1.83B1.31B864M909M1.36B

Quest Diagnostics Incorporated

NYSE:DGX

Intrinsic Alpha fair value

Locked

Current Price

$259.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.